Lipella Pharmaceuticals (LIPO) Competitors $2.93 -0.15 (-4.87%) Closing price 03:57 PM EasternExtended Trading$2.56 -0.38 (-12.80%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. QNTM, CLNN, CARA, GDTC, ENLV, CYTH, TPST, TENX, CASI, and EGRXShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Quantum Biopharma (QNTM), Clene (CLNN), Cara Therapeutics (CARA), CytoMed Therapeutics (GDTC), Enlivex Therapeutics (ENLV), Cyclo Therapeutics (CYTH), Tempest Therapeutics (TPST), Tenax Therapeutics (TENX), CASI Pharmaceuticals (CASI), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Quantum Biopharma Clene Cara Therapeutics CytoMed Therapeutics Enlivex Therapeutics Cyclo Therapeutics Tempest Therapeutics Tenax Therapeutics CASI Pharmaceuticals Eagle Pharmaceuticals Lipella Pharmaceuticals (NASDAQ:LIPO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Which has more volatility and risk, LIPO or QNTM? Lipella Pharmaceuticals has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Is LIPO or QNTM more profitable? Quantum Biopharma has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -882.82%. Quantum Biopharma's return on equity of -84.21% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-882.82% -192.33% -154.24% Quantum Biopharma N/A -84.21%-62.63% Does the MarketBeat Community prefer LIPO or QNTM? Lipella Pharmaceuticals received 1 more outperform votes than Quantum Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformLipella PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesQuantum BiopharmaN/AN/A Which has better valuation & earnings, LIPO or QNTM? Lipella Pharmaceuticals has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K13.92-$4.62M-$4.08-0.72Quantum BiopharmaN/AN/A-$17.90M-$15.98-0.77 Does the media prefer LIPO or QNTM? In the previous week, Quantum Biopharma had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 4 mentions for Quantum Biopharma and 2 mentions for Lipella Pharmaceuticals. Lipella Pharmaceuticals' average media sentiment score of -0.24 beat Quantum Biopharma's score of -0.75 indicating that Lipella Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipella Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do institutionals & insiders hold more shares of LIPO or QNTM? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryLipella Pharmaceuticals beats Quantum Biopharma on 9 of the 13 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.47M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-0.698.9226.8419.71Price / Sales13.92253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.686.466.794.50Net Income-$4.62M$143.98M$3.23B$248.18M7 Day Performance22.59%3.04%4.07%1.14%1 Month Performance28.51%7.44%12.52%15.20%1 Year Performance-49.70%-2.46%16.83%6.56% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals0.9453 of 5 stars$2.93-4.9%N/A-49.0%$7.47M$536,357.00-0.694Positive NewsEarnings ReportQNTMQuantum BiopharmaN/A$9.12+0.6%N/AN/A$24.68MN/A-0.59N/ANews CoverageEarnings ReportCLNNClene2.5288 of 5 stars$2.72+3.4%$40.00+1,370.6%-65.1%$24.43M$342,000.00-0.52100CARACara Therapeutics1.2352 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeGDTCCytoMed Therapeutics1.5888 of 5 stars$2.30+3.8%$5.00+117.0%-1.0%$24.29M$69,501.000.00N/AGap UpENLVEnlivex Therapeutics2.0607 of 5 stars$1.00-1.7%$10.00+897.0%-30.3%$23.72MN/A-1.0270News CoverageCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809TPSTTempest Therapeutics1.9568 of 5 stars$6.87+5.9%$30.00+336.7%-84.2%$23.72MN/A-4.4920Analyst RevisionTENXTenax Therapeutics2.089 of 5 stars$5.71+2.5%$18.00+215.2%+60.0%$23.69MN/A-1.079News CoverageEarnings ReportAnalyst RevisionCASICASI Pharmaceuticals3.9411 of 5 stars$1.92+2.0%$4.00+107.9%-41.0%$23.66M$28.54M-0.86180Earnings ReportAnalyst ForecastAnalyst RevisionEGRXEagle PharmaceuticalsN/A$1.99+4.7%N/A-57.9%$23.38M$257.55M0.00100Gap Down Related Companies and Tools Related Companies QNTM Competitors CLNN Competitors CARA Competitors GDTC Competitors ENLV Competitors CYTH Competitors TPST Competitors TENX Competitors CASI Competitors EGRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
